MBio Diagnostics inks development deal with U.S. Army; VolitionRx teams up with University of Oxford to develop endometriosis biomarkers;

> MBio Diagnostics inked a three-year development contract with the U.S. Army's Walter Reed Army Institute of Research to develop a point-of-care diagnostic device for malaria. Release

> VolitionRx is teaming up with the University of Oxford to develop biomarkers for endometriosis diagnosis. Release

> The FDA rejected Aeterna Zentaris' experimental growth hormone diagnostic test, saying that the Canada-based company's trial did not meet its end goal. Story

> Genetic Technologies dismissed its patent infringement lawsuit against Agilent Technologies over technology for analyzing noncoding DNA sequences. Release

> Thermo Fisher Scientific ($TMO) priced an offering of $800 million senior notes. The company plans to use proceeds to repay debt. Release

> Almac Group rolled out a next-generation sequencing test for P53 mutations. Release

Suggested Articles

The FDA has cleared its first fully disposable duodenoscope, following years of reports of infections being transmitted between patients.

OR-focused AI provider Caresyntax has garnered $45.6 million in new funding and picked up a data analytics firm to broaden its footprint.

A study of Foundation Medicine’s FoundationOne liquid biopsy test found it was able to predict the risk that a person’s breast cancer would return.